Evidence map›Paper›PMID 42619408›Full record

ArticlemAbs2026

Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion.

Jamie Thomas, Gang Xu, Hannah Lock, Qin Song, Yumei Yin, Wanying Luo, Kyu Hong, Liguang Lou, Changyu Wang, Leslie Chinn and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jamie ThomasOuro Medicines, South San Francisco, CA, USA.
Gang XuKeymed Biosciences, Chengdu, China.
Hannah LockOuro Medicines, South San Francisco, CA, USA.
Qin SongKeymed Biosciences, Chengdu, China.
Yumei YinKeymed Biosciences, Chengdu, China.
Wanying LuoKeymed Biosciences, Chengdu, China.
Kyu HongOuro Medicines, South San Francisco, CA, USA.
Liguang LouShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Changyu WangKeymed Biosciences, Chengdu, China.
Leslie ChinnOuro Medicines, South San Francisco, CA, USA.
Neelufar MozaffarianOuro Medicines, South San Francisco, CA, USA.
Jaideep DudaniOuro Medicines, South San Francisco, CA, USA.
Paul BessetteOuro Medicines, South San Francisco, CA, USA.
Charlie ZhouOuro Medicines, South San Francisco, CA, USA.
Ruth LanOuro Medicines, South San Francisco, CA, USA.
Bo ChenKeymed Biosciences, Chengdu, China.
Nishant MehtaOuro Medicines, South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B cell maturation antigen (BCMA) is a validated target for plasma cell depletion; however, T cell-redirecting approaches must balance potent cytotoxicity with controlled T cell activation. Here, we describe the design and preclinical characterization of gamgertamig, an affinity-tuned BCMA×CD3 bispecific T-cell engager engineered to promote target-dependent activity. Gamgertamig is a humanized IgG4-based 1 + 1 bispecific antibody incorporating Fc-silencing mutations and a reduced-affinity CD3-binding arm, resulting in a >50-fold affinity bias toward BCMA relative to CD3. Gamgertamig exhibited high-affinity binding to BCMA and mediated potent, antigen-dependent cytotoxicity across B cell and myeloma cell lines spanning a wide range of target densities, with sub-nanomolar EC

Indexed as

Antibodies, BispecificB-Cell Maturation AntigenB-LymphocytesCD3 ComplexLymphocyte DepletionMultiple MyelomaT-LymphocytesAnimalsAntibody AffinityHumansMiceAntibodies, BispecificB-Cell Maturation AntigenCD3 ComplexTNFRSF17 protein, humanAffinity-tunedautoimmunityBCMAbispecific antibodyimmune resetT-cell engager

Identifiers

PMID42619408
PMCPMC13501987

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.